Type 1 and type 2 IFNs activate STAT1-3 and may help control the growth of CLL cells, particularly in the presence of the bruton’s tyrosine kinase-inhibitor ibrutinib (53, 117). Here, STAT1 is linked to B-cell chronic lymphocytic leukemia.